Advancing NPC research and other grant funding is necessary to help us find a cure for NPC disease.
This page is dedicated to organizations that have active grant funding program.  Please visit each website to learn more about their funding priorities and how to apply.
Therapeutics
Ara Parseghian Medical Research Fund

The APMRF grant program supports an international research program to expedite a treatment and cure for NPC disease;  to promote collaborative research efforts among the world’s leading experts in cholesterol metabolism, cell biology, neurobiology, genetics, pharmacology and other areas of science; and to study similar and further the cause of other neurodegenerative diseases as well as cholesterol storage disorders.

  • Website
  • Grants range from $100K - $250K
  • Deadline: March 1, 2021
NP-UK

Alongside providing support and care for those living with or affected by Niemann-Pick disease, one of our other main areas of focus is providing information relating to research. NPUK shares knowledge, expertise and works in partnership and collaboration with other not-for-profit organisations, medical authorities and scientific institutions across the world, in order to facilitate progress towards therapeutic interventions for the Niemann-Pick disease.

Where possible, NPUK also funds appropriate research in order to improve medical and scientific knowledge and promote understanding of the disease.

  • Website
  • Please visit the NPUK website to learn more about how to apply for a grant.
Support of Accelerated Research for Niemann-Pick Type C

Support Of Accelerated Research for Niemann-Pick C, or SOAR-NPC, was created by parents and scientists as a grassroots response to the absence of treatments for this terminal disease.

The number one goal of SOAR-NPC is to work as quickly as possible to find evidence-based treatments and ultimately a cure for Niemann-Pick Type C disease, a rare neurological illness.

SOAR scientists are internationally recognized in NPC research from institutions including Washington University in St. Louis, Albert Einstein College of Medicine, and University of Pennsylvania.  SOAR family foundations are dedicated to raising money and awareness to combat this deadly disease.

  • Website
  • Please visit the SOAR website to learn more about how to apply for a grant.
National Niemann-Pick Disease Foundation, Inc.
The research is funded by the National Niemann-Pick Disease Foundation is made possible in great part due to the efforts of our NPD families and their extended support network via local community-sponsored events. A key element to the foundation’s research strategy is the ability to track funds raised within the communities of our family membership. Great care is given to identify monies received at the NNPDF Central Offices through family fundraising efforts so that funds are used for the donor’s wishes.
  • Website
  • Please visit the NNPDF website to learn more about how to apply for a grant.
NP Canada
Niemann-Pick Canada is devoted to finding a cure for Niemann-Pick Type C disease. Our mission is to fund promising science and research to progress knowledge of and treatment for Niemann-Pick diseases. 
  • Website
  • Please visit the NP Canada website to learn more about how to apply for a grant.
Australian NPC Disease Foundation
The Australian NP-C Disease Foundation strongly supports research to finding new treatment options that will provide better health outcomes for NP-C patients. 
  • Website
  • Please visit the Australian NPC Disease Foundation website to learn more about how to apply for a grant.
NP Canada
Our mission is to fund and support the research and education necessary to accelerate a cure for rare neurodegenerative genetic diseases that affect children and currently have no cure. We have begun our journey with a focus on Niemann-Pick Disease Type C.
  • Website
  • Please visit the Firefly Fund website to learn more about how to apply for a grant.

*If you are a grant funding NPC organization and would like to be added please contact the NPC Accelerator team.